NASDAQ:PBYI - Puma Biotechnology, Inc.
$9.70
 $-0.50
-4.90%
12:45PM EDT
2019-07-22
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  PBYI     avg for
industry  
  avg for
sector  
42 stocks weight:  13. 17   217. 37   399. 45  
42 stocks rank:  3. 50 K 1. 27 K 716. 99  
# analyst opinions:  7. 00   13. 21   13. 71  
mean recommendation:  3. 20   2. 10   2. 04  

quick ratio:  2. 38   5. 49   1. 88  
current ratio:  2. 53   5. 87   2. 36  

target price low:  16. 00   83. 44   114. 90  
target price avg:  21. 86   106. 20   137. 90  
target price high:  28. 00   132. 30   158. 97  
1-yr high:  51. 75   111. 86   142. 57  
last close:  10. 20   86. 79   125. 44  
50-day avg:  14. 15   86. 68   122. 63  
200-day avg:  26. 61   89. 22   121. 38  
1-yr low:  10. 20   69. 78   100. 51  
volume:  1. 10 M 2. 62 M 3. 43 M
50-day avg volume:  1. 35 M 3. 20 M 4. 16 M
200-day avg volume:  1. 21 M 2. 99 M 4. 75 M

1-day return:  -3. 32 % -1. 30 % -0. 99 %
this week return:  -12. 52 % 0. 45 % -0. 20 %
12-wk return:  -69. 47 % 0. 94 % 4. 84 %
52-wk return:  -79. 61 % -1. 30 % 10. 55 %

enterprise value (EV):  423. 17 M 45. 10 B 122. 38 B
market cap:  393. 85 M 38. 96 B 108. 40 B
EBITDA:  -53. 25 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -7. 95   5. 38   11. 93  
enterprise/revenue (EV/R):  1. 49   57. 92   10. 21  
total revenue:  283. 54 M 9. 91 B 39. 98 B
total debt:  179. 72 M 10. 90 B 17. 48 B
debt/equity:  413. 44   57. 18   120. 05  
net income (common):  -99. 32 M 2. 07 B 4. 05 B

shares outstanding:  38. 61 M 538. 09 M 1. 24 B
shares:  30. 89 M 548. 00 M 1. 22 B
shares short:  6. 84 M 10. 98 M 11. 87 M
shares short prior month:  4. 34 M 9. 32 M 12. 05 M
short ratio:  5. 39   5. 60   3. 34  
short % of float:  19. 91 % 6. 48 % 2. 64 %
total cash/share:  3. 90   10. 98   9. 19  
total cash:  150. 40 M 5. 93 B 6. 10 B
free cash flow:  7. 89 M 2. 92 B 4. 55 B
operating cash flow:  -33. 98 M 3. 80 B 5. 78 B

book value:  1. 13   13. 35   27. 45  
price/book:  9. 05   4. 60   8. 78  
gross profits:  216. 37 M 7. 44 B 36. 13 B
operating margins:  -21. 67 % -308. 40 % -28. 55 %
EBITDA margins:  -18. 78 % 13. 17 % 23. 38 %
profit margins:  -35. 03 % 10. 44 % 14. 18 %
gross margins:  87. 22 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -2. 60   2. 10   4. 23  
forward EPS:  -2. 06   3. 45   7. 10  
P/E:  -3. 92   1. 90   32. 10  
forward P/E:  -4. 95   6. 46   15. 47  
PE/G:  -0. 08   0. 70   -0. 54  
growth:  48. 90 % 265. 63 % 79. 11 %
earnings high:  -0. 74   0. 89   1. 68  
earnings avg:  -0. 99   0. 70   1. 57  
earnings low:  -1. 37   0. 46   1. 46  
revenue high:  61. 80 M 2. 57 B 11. 07 B
revenue avg:  53. 50 M 2. 51 B 10. 91 B
revenue low:  50. 00 M 2. 45 B 10. 73 B
return on assets:  -15. 33 % -2. 34 % 5. 28 %
return on equity:  -196. 81 % -90. 08 % 133. 53 %
revenue growth:  48. 90 % 265. 25 % 73. 68 %
revenue/share:  7. 43   12. 72   60. 04  

beta (1yr vs S&P500):  1. 59   1. 27   0. 91  
sharpe (1yr):  -1. 30   0. 16   0. 77  

held % insiders:  13. 44 % 6. 06 % 3. 29 %
held % institutions:  100. 94 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : PBYI
.    112.458 =       112.458 :: --> INITIAL WEIGHT <--
.    - 2.604 =       109.854 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.081 =       228.647 :: P/E factor
.     x 1.88 =       429.787 :: PE/G factor
.     x 1.58 =       679.034 :: beta factor
.    x 0.853 =       579.342 :: sharpe factor
.     x 2.43 =      1408.075 :: current ratio factor
.    x 1.313 =      1849.161 :: quick ratio factor
.    x 1.089 =      2013.403 :: short ratio factor
.    x 1.647 =      3316.382 :: revenue growth factor
.    x 1.026 =      3401.805 :: EV/R factor
.      x 1.1 =      3742.809 :: price-to-book factor
.    x 1.578 =       5904.82 :: debt-to-revenue factor
.    x 2.284 =      13489.17 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =     28607.737 :: sector+industry 1-year gains factor
.    x 1.009 =     28877.453 :: industry 12-weeks return factor
.    x 1.308 =     37768.491 :: industry 2-weeks return factor
.    x 0.819 =     30950.189 :: company one-year gains+dividend factor
.    x 0.913 =     28268.098 :: company 13 weeks' performance factor
.    x 0.978 =     27637.046 :: "drift" penalty 1 days ago
.    x 0.977 =     27014.171 :: "drift" penalty 2 days ago
.    x 0.981 =     26499.513 :: "drift" penalty 3 days ago
.    x 0.979 =     25951.858 :: "drift" penalty 5 days ago
.    / 2.003 =     12956.928 :: overall "drift" factor
.    x 0.886 =     11474.381 :: largest single-day jump factor
.    x 0.143 =      1643.894 :: low price factor
.    x 0.142 =       232.921 :: notable returns + performance factor
.    x 3.394 =       790.522 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.794 =       628.068 :: forward EPS factor
.    x 0.925 =       581.167 :: forward P/E factor
.    x 1.185 =       688.516 :: industry recommendation factor
.    x 1.003 =        690.42 :: factor historical industry gain for week 29
.    x 1.936 =      1336.371 :: target low factor
.    x 1.356 =      1812.644 :: target mean factor
.    x 1.055 =      1913.214 :: target high factor
.   x 11.033 =     21108.438 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        12.054 :: reduced for readability
.    + 0.881 =        12.935 :: add/subtract for investor sentiment
.    + 0.235 =         13.17 :: earnings report in 17 days
.                               --> FINAL WEIGHT <--
.                      13.17 :: FINAL WEIGHT for NASDAQ:PBYI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org